NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.…
Neuraxis Inc (NRXS) Q3 2026 Earnings Call Highlights: Record Revenue, 150% Growth, and ...
NeurAxis (NYSEAMERICAN: NRXS) is listed on NYSE American, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 24 employees.
The shares were at 4.220 USD on 20 November 2026, up 66.1% over 52 weeks. Its 52-week range is 2.210 USD to 9.330 USD: the price is 54.8% below the high and 91.0% above the low.
Its market capitalisation is 59.90M USD.
NeurAxis reports return on equity of -229.5%, an operating margin of -186.2% and revenue up 149.9% year over year.
It holds more cash than debt, a net cash position of 4.05M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 11.00 USD is 160.7% above the current price.